The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | The prevalence of infections with bispecific use and managing patients who develop an infection
Meral Beksac, MD, PhD, Istinye University Ankara Liv Hospital, Ankara, Turkey, shares the findings of a small study comparing infection rates and intravenous immunoglobulin (IVIg) use among patients with multiple myeloma (MM) treated with daratumumab to those receiving belantamab mafodotin plus pomalidomide in the DREAMM-8 trial (NCT04484623). Dr Beksac highlights the increasing prevalence of infections with the advent of novel immunotherapy approaches and briefly comments on the management of patients who develop an infection. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
